IDPC and TNI offer guidance on WHO's cannabis scheduling recommendations.

INPUD shares the results of a three-year research programme exploring how community involvement impacts the quality and accessibility of harm reduction services for people who use drugs.

The EMCDDA provides an overview of the European drug situation's ongoing trends and developments.

INPUD aims to amplify the voices of leading advocates and identify common features of the movement of people who use drugs.

Scheim et al. conclude on the need to broaden the range of metrics used to assess the positive impacts of decriminalisation and legal regulation.

ICER addresses the US' escalating opioid overdose epidemic and assesses a multi-faceted approach to unifying the health sector in spreading awareness and providing treatment to those seeking help.

Despite medicinal cannabis products now being legal in the UK, patients still face stiff resistance from their prescribers in gaining access to the treatment they need.

Policy Bristol calls to address the illicit tramadol trade's root causes. Underfunded healthcare, migration overflow, and unemployment are the primary concerns; not people with drug dependencies.

INPUD's 2018/19 report recaps their successes in advocating for people who use drugs and campaigning for human rights and greater access to health services across the world.

Sumnall et al.'s research suggests insights into the life histories of people who experience challenges related to their drug use can elicit less stigmatising responses.

UNAIDS offers a pandemic response guide focusing on justice, access to services and participation, while highlighting the impacts public health measures have on the most vulnerable.

This GDS edition focused on the impact of the pandemic on people's use of drugs, mental health and relationships.

ECOWAS acknowledges the importance of ensuring access to harm reduction services by removing socio-structural barriers, including through decriminalisation.

Ross et al. discuss dynamics of risk and privilege concerning the lived/living experiences of drug researchers who use drugs.

A.Greer et. all highlight peer workers are particularly vulnerable to precarious working conditions, entrenching inequities and imperilling the harm reduction response.

BERL costs the potential impact of a legal cannabis market in New Zealand / Aotearoa.

IDPC presents twenty principles to guide the responsible legal regulation of cannabis markets.

The Scottish Drugs Forum inventories the needs of three specific communities of people who use drugs to facilitate training and service development.

Barrot et al. report increased provision of opioid overdose education and naloxone distribution in needle and syringe programmes in the US, but coverage remains unequal.

The publication addresses the drugs and development nexus from a range of critical viewpoints, highlighting gaps and contradictions, and exploring opportunities for enhanced linkages between drug policy and development programming.